All In Biotech

BLA 208673 · Sanofi-Aventis US

Soliqua 100/33

Insulin Glargine, Lixisenatide · Subcutaneous · Insulin Analog; GLP-1 Receptor Agonist

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Nov 21, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

679

239 Phase 3, 12 recruiting

FAERS reports

3,660

655 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2026.

SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use ( 1 ) : Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended. Not recommended for the treatment of diabetic ketoacidosis. Has not been studied in combination with prandial insulin. Limitations of Use : SOLIQUA 100/33 contains lixisenatide. Coadministration with any other product containing lixisenatide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions (5.5) ] . SOLIQUA 100/33 is not recommended for the treatment of diabetic ketoacidosis. SOLIQUA 100/33 has not been studied in combination with prandial insulin.

Mechanism: SOLIQUA 100/33 SOLIQUA 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. Insulin glargine The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis. Lixisenatide Lixisenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SOLIQUA 100/33 · INSULIN GLARGINE 300 UNITS/3ML; LIXISENATIDE 99MCG/3ML (100 UNITS/ML · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glargine" as an intervention, any sponsor and status, largest first.

All 679 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased467
  • product storage error402
  • off label use355
  • accidental exposure to product340
  • exposure via skin contact203
  • nausea154
  • inappropriate schedule of product administration149
  • visual impairment146
  • drug ineffective123
  • blood glucose decreased100
  • device issue99
  • diarrhoea80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
2017222
2018330
2019316
2020336
2021388
2022458
2023414
2024400
2025457
2026338

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Soliqua 100-33 (Insulin Glargine/Lixisenatide)

2024 spending

$300M

Beneficiaries

59,472

273,407 claims

Per beneficiary

$5,048

$56.01 per unit

View as table
YearSpending
2020$121,393,843
2021$165,620,858
2022$215,943,202
2023$302,998,642
2024$300,185,496

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 986 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.